| 23.88 -1.73 (-6.76%) | 03-03 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 31.08  |
1-year : | 38.77 |
| Resists | First : | 26.61 |
Second : | 33.2 |
| Pivot price | 28.24  |
|||
| Supports | First : | 15.97 |
Second : | 13.28 |
| MAs | MA(5) : | 26.39 |
MA(20) : | 25.6 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | 1.5 |
Signal : | 2.1 |
| %K %D | K(14,3) : | 44.1 |
D(3) : | 56.5 |
| RSI | RSI(14): 47.7 |
|||
| 52-week | High : | 33.2 | Low : | 13.88 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ EVMN ] has closed below the lower bollinger band by 2.2%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 25.77 - 25.95 | 25.95 - 26.09 |
| Low: | 23.43 - 23.66 | 23.66 - 23.84 |
| Close: | 23.56 - 23.87 | 23.87 - 24.11 |
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. It develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products includes EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.
Fri, 27 Feb 2026
EVMN Technical Analysis & Stock Price Forecast - Intellectia AI
Thu, 26 Feb 2026
Evommune (NYSE:EVMN) Trading Down 10.2% - Time to Sell? - MarketBeat
Wed, 18 Feb 2026
Morgan Stanley Maintains Overweight on Evommune (EVMN) Feb 18 2026 - Meyka
Sun, 15 Feb 2026
Evommune, Inc. Common Stock (NYSE:EVMN) Stock Quote - FinancialContent
Thu, 12 Feb 2026
Evommune Inc (EVMN-N) Insider Trade Summaries - The Globe and Mail
Thu, 12 Feb 2026
Evommune Stock Cools Off After Big Rally On Successful Eczema Trial - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 32 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 12.1 (%) |
| Held by Institutions | 103.1 (%) |
| Shares Short | 2,510 (K) |
| Shares Short P.Month | 1,040 (K) |
| EPS | -2.09 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -117.78 |
| Profit Margin | 0 % |
| Operating Margin | -133.3 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.41 |
| Sales Per Share | 0.41 |
| EBITDA (p.s.) | -2.27 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -78 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -11.43 |
| PEG Ratio | 0 |
| Price to Book value | -0.21 |
| Price to Sales | 57.89 |
| Price to Cash Flow | -9.62 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|